March 12-13, 2020, in Santa Clara, California

Every two years, the Epilepsy Foundation holds its Pipeline Conference to bring together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation, and product development. This exciting meeting provides a forum for surveying new therapies in development, exploring future advancements, and encouraging collaborations and partnerships.

The 2020 Pipeline Conference will take place March 12-13, 2020, at the Santa Clara Marriott in Santa Clara, California. This conference will also feature a Community Day on Saturday, March 142020, where people living with epilepsy and their family, friends, and supporters gather for a day of learning, support, and networking. The event will also include the 2020 Epilepsy Foundation Shark Tank Competition.

Speakers and attendees will include:

  • Emerging biotech and medical technology companies
  • Major pharmaceutical and device companies
  • Researchers and innovators at the cutting edge of epilepsy and central nervous system treatment advances
  • Investors and venture capitalists

Registration Open Now

Registration is now open for the 2020 Epilepsy Pipeline Conference.

Cost to attend:

  • $600: for clinicians, researchers, and other professionals
  • $150: for professionals representing a non-profit 
  • $150: for individuals living with epilepsy or their family members who are not attending on behalf of a for-profit company

Hotel booking: The Santa Clara Marriott is offering a special group rate for attendees. Make your reservation here. Please book by February 18, 2020.

Questions? Contact Dr. Kathleen Farrell, senior director of clinical research, at

Travel Grants

The Epilepsy Foundation, the Epilepsy Study Consortium, and the Pediatric Epilepsy Research Foundation have pooled their funds to provide travel grants to the conference. Please note that each foundation sponsors a different type of travel grant (Epilepsy Fellow/Junior Faculty and Pediatric Epilepsy Fellows). Please see Types of Travel Grants in this document to select the one that best applies to you. Successful applicants are expected to attend all sessions and are invited to participate in mentoring luncheons with experienced clinicians and scientists during the conference.

Application due date: Friday, January 17, 2020 Extended to January 24, 2020 by 5:00 p.m. ET. Applications received after this date will not be considered.

Refer to the Travel Grant Guidelines for more information.

Conference Agenda

Times are pacific standard time (PST). Please note that the agenda will be continually updated as speakers confirm their slots.

Day 1 – Thursday, March 12, 2020

Welcome and Overview – 8:00-8:15 A.M.

  • Jacqueline French MD, Chief Medical and Innovation Officer, Epilepsy Foundation
  • Robert Smith, Interim CEO, Epilepsy Foundation
  • Kerry Youker, Board Chair, Epilepsy Foundation Northern California

Session I: We know where we've been. Do we know where we are going? – 8:15-9:05 a.m.

  • Lecture: Past Successes – Sonya Dumanis PhD, Senior Director of Innovation, Epilepsy Foundation
  • Panel: Future Challenges  Daniel Fischer, Founder of Tevard Biosciences; Greg Mayes, CEO & Founder of Engage Therapeutics; Yssa DeWoody, President of Ring14 USA; Ilene Penn Miller, Rare Epilepsy Network

Session II: Diagnosis and Detection Devices – 9:05-11:25 A.M.

  • Lecture: Can SUDEP be avoided with devices?– Sam Lhatoo MD, FRCP, UT Health
  • Lecture: My Seizure Gauge, Seizure Forecasting, and the Future of Therapeutics – Dean Freestone PhD, Co-Founder, Seer Medical
  • 3D Optical Scanner and Machine Vision Platform, Advanced Scanners  Aaron Bernstein, CTO, Co-Founder & CEO
  • SPEAC System, Brain Sentinel – Luke Whitmire PhD, Chief Scientific Officer
  • SeizeIT, Byteflies & UCB – Benjamin Vandendriessche, CMO & Gergely Vertes, Seizure Freedom Mission Solution Accelerator
  • Embrace Platform and Device, Empatica – Matteo Lai, Co-Founder & CEO
  • Epihunter Tracker, Epihunter – Dirk Loeckx PhD, Chief Scientific Officer
  • Nelli Seizure Monitoring Tool, Go North Medical, Neuro Event Labs – Glen Fotland, Founder
  • Captureproof Platform, Captureproof  – Meghan Conroy, Founder & CEO
  • TMS-EEG, Kings College London – Isabella Premoli MD
  • UNEEG 24/7 SubQ, UNEEG Medical – Lykke Blaabjerg, Head of Clinical Affairs
  • Epi-Minder sub-scalp system, Epi-Minder – Mark Cook, Director of Neurology, Melbourne University

Networking Break – 11:25-11:45 A.M.

Session III: Therapeutic Devices – 11:45 A.M.-12:15 P.M.

  • Cathodal Transcranial Direct Current Stimulation, tDCS, Neuroelectrics  –Alexander Rotenburg MD
  • DyNeuMo implantable device and platform, DyNeuMo
  • RNS System, NeuroPace – David King-Stephens MD, California Pacific Medical Center

Session IV: Investor Panel – 12:15-12:55 P.M.

Networking Lunch – 12:55-1:55 P.M.

Session V: What We Still Need in Drugs for Focal Epilepsy – 1:55-3:50 P.M. 

  • Lecture: What would make a new focal epilepsy drug successful in the marketplace? – Daniel Friedman MD, New York University Langone Medical Center
  • 2-Deoxy-d-Glucose (2DG), University of Wisconsin –Thomas Sutula MD, PhD
  • Inhibitory interneuron cell therapy, Neurona Therapeutics  Cory Nicholas PhD, CEO & Co-Founder
  • Adenosine kinase inhibitors, Robert Wood Johnson Medical School  Detlev Boison PhD
  • Revivo-5061, Revivo Therapeutics  Doug Cowart PharmD, CEO
  • Sage-324, Sage Therapeutics  Helen Colquhoun, Vice President
  • Cenobamate and Carisbamate, SK Life Sciences  William Rosenfeld MD
  • XEN1101, Xenon Pharma  Ernesto Aycardi MD, Chief Medical Officer
  • NC201, NeuCyte  Hui Liu PhD, Director, Drug Discovery
  • Padsevonil, UCB  Konrad Werhahn MD, Senior Medical Director, Global Clinical Development

Networking Break – 3:50-4:10 P.M.

Update from 2019 Shark Tank Winners – 4:10-4:30 P.M.

  • Rachel Kuperman MD, CEO of Eysz, Inc.
  • Jody McNannay, Co-Founder, Curadite, Inc. and parent of a daughter with epilepsy

2020 Shark Tank Competition – 4:30-6:30 P.M.

  • Aditya Kadambi from Mocxa for their automated privacy enhancement for seizure videos
  • Atilla Borbath from Synergia Medical for their NAO-VNS product
  • Boris Goldstein PhD from Brain Scientific for his graphene electrodes in under the skin EEG implants
  • Jong Woo Lee MD along with Product Architectures for their night-time SUDEP prevention device
  • Keely McCarthy, parent of a child living with epilepsy, for her emergency epilepsy band

Accelerator Award Reception & Presentation – 6:30-8:30 P.M.

Day 2 – Friday, March 13, 2020

Day 2 Welcome – 8:00-8:15 A.M.

  • Kathleen Farrell MB BCh BAO, Senior Director of Clinical Research, Epilepsy Foundation 
  • Sylvia Olvera MD, Kaiser Permanente 

Session VI: Screening – 8:15-9:10 A.M.

  • Lecture: Status report on NINDS Translational Epilepsy Research – Brian Klein PhD, NINDS
  • Lecture: Screening Across the Board: Where are we and where should we be going? – Mike Rogawski MD, PhD, University California Davis
  • NeuCyte platform, NeuCyte – Thomas Portmann PhD, Associate Director, Head of Research
  • CUE Platform, SynapCell – Corinne Roucard PhD, CEO and Head of Business Development

Session VII: Genetics – 9:10-9:55 A.M.

  • Lecture: Mechanisms of intervention in single gene diseases – Annapurna Poduri MD, MPH, Boston Children’s Hospital
  • STK-001, Stoke Therapeutics​ – Barry Ticho MD, PhD, Chief Medical Officer
  • Atalurin, PTC Therapeutics – Quintus Ngumah, PhD, VP Clinical Development
  • EXT101, Encoded Therapeutics – Rosie O’Donnell MD, Senior Advisor, Clinical Development

Networking Break – 9:55-10:15 A.M.

Session VIII: Data-Driven Solutions – 10:15-11:50 A.M.

  • Lecture: What can we learn from aggregated data and why should we be capturing it? – David Voccola, Prometheus Research, Co-Founder
  • ​Epilepsy Data Experiential Network (EDEN) – Jacqueline French MD, Chief Medical Innovation Officer, Epilepsy Foundation
  • Epilepsy Learning Healthcare System – Brandy Fureman PhD, Vice President of Research and New Therapies, Epilepsy Foundation
  • Seer Platform, Seer Medical – Dean Freestone PhD, Co-Founder
  • Using AI to predict AED response, UCB – Martin Armstrong PhD, Head of Genetics
  • Doc.AI platform, Doc.AI – Sam De Brouwer PhD, Co-Founder
  • Predictor of AED Response through Advanced Data analysis of EEG (PARADE), Epilog – Gregor Strobbe PhD, Co-CEO
  • Epistemic app, Epistemic – Paula Gomez PhD, MBA, CEO and Co-founder
  • BioSerenity platform, BioSerenity – Bruce Lavin MD, MPH, Chief Medical Officer

Session IX: Rare and Ultra-Rare Diseases – 11:50 A.M.-12:20 P.M.

  • Lecture: Efficient trials and Ultra-Rare Diseases - An Overview of the 2019 Research Roundtable for Epilepsy – Dennis Dlugos MD, Children’s Hospital of Philadelphia
  • Lecture: Rare Populations Interactions with FDA
    • Steve Roberds PhD, Chief Scientific Officer Tuberous Sclerosis Alliance

Networking Lunch – 12:20-1:20 P.M.

Session IX Continued: Rare and Ultra-Rare Diseases – 1:20-3:20 P.M.

  • KB-3061, Knopp Biosciences – Steven Dworetzky PhD, Vice President of Discovery Research
  • Tak-935/OV935, Takeda Pharmaceuticals – Mahnaz Asgharnejad PharmD, Vice President of Clinical Development
  • UX-068, Ultragenyx – Melanie Brandabur MD, Medical Director
  • VAL-0417 and VAL-1221, Valerion Therapeutics – Matthew Gentry PhD
  • XEN-496,  Xenon Pharma – Ernesto Aycardi, Chief Medical Officer
  • ZX008, Zogenix​ – Glenn Morrison PhD, Vice President of Global Clinical Development
  • Anavex 2-73, Anavex Life Sciences​ – Walter Kaufmann MD, Chief Medical Officer
  • AE116, Aeovian Pharmaceuticals – Stelios Tzannis PhD, President & CEO
  • Natalizumab, Biogen – Kim Parkerson MD, PhD, Medical Director, Epilepsy and Neurodevelopment  
  • PRAX-330, Praxis Precision Medicines – Kiran Reddy MD
  • NBI-921352, Neurocrine Biosciences – Dietrich Haubenberger MHSc, MD, Medical Director, Early Clinical Development
  • Epidiolex for Tuberous Sclerosis, Greenwich Biosciences – Farhad Sahebkar MD, Senior Medical Director

Session X: Reformulated Drugs and Other Therapies – 3:20-4:30 P.M.

  • Buccal diazepam, Aquestive Therapeutics – Michael Rogawski MD, PhD, Consultant
  • Staccato alprazolam, Engage Therapeutics – Jouko Isojarvi MD, PhD, Chief Medical Officer
  • Novel intramuscular diazepam, Xeris Pharmaceuticals – Anh Nguyen MD, Director, Strategy Operations
  • CT-010, Cerebral Therapeutics – Dan Abrams MD, CEO
  • NRL-03, Neurelis – Craig Chambliss, CEO & Co-Founder
  • The Gut Brain Axis and Epilepsy, Bloom Science – Christopher Reyes PhD, Co-Founder & CEO
  • Ganaxolone IV, Marinus Pharmaceuticals – Julia Tsai PhD, Vice President of Clinical Development

Closing Remarks – 4:30-4:40 P.M.

  • Jacqueline French MD, Chief Medical and Innovation Officer, Epilepsy Foundation

Final Networking Reception – 4:40-5:30 P.M.

Watch Footage from the 2018 Pipeline Conference

Authored By: 
Research Team
Authored Date: